Board M, Bollen M, Stalmans W, Kim Y, Fleet G W, Johnson L N
Oxford Centre for Molecular Sciences, University of Oxford, U.K.
Biochem J. 1995 Nov 1;311 ( Pt 3)(Pt 3):845-52. doi: 10.1042/bj3110845.
A series of glucose-analogue inhibitors of glycogen phosphorylase b (GPb) has been designed, synthesized and investigated in crystallographic binding and kinetic studies. The aim is to produce a compound that may exert more effective control over glycogen metabolism than the parent glucose molecule and which could alleviate hyperglycaemia in Type-II diabetes. N-Acetyl-beta-D-glucopyranosylamine (1-GlcNAc) has a Ki for muscle GPb in crude extracts of 30 microM, 367-fold lower than that of beta-D-glucose [Board, Hadwen and Johnson (1995) Eur. J. Biochem. 228, 753-761]. In the current work, the effects of 1-GlcNAc on the activation states of GP and glycogen synthase (GS) in cell-free preparations and in isolated hepatocytes are reported. In gel-filtered extracts of liver, which lack ATP for kinase activity, 1-GlcNAc produced a rapid and time-dependent inactivation of GP with a subsequent activation of GS. Effects of 1-GlcNAc on both enzymes were stronger than those of glucose, with 0.8 mM 1-GlcNAc being equipotent with 50 mM glucose. At 1 mM, 1-GlcNAc enhanced the dephosphorylation of exogenous GPa by liver extracts (600%) and by muscle extracts (75%). This represents an approximately 500-fold improvement on glucose for the liver activity and 40-fold for the muscle activity. In whole hepatocytes, 1-GlcNAc showed an approximately 5-fold enhancement of glucose effects for GP inactivation but failed to elicit activation of GS. Glucose-induced activation of GS in whole hepatocytes was reversed by subsequent addition of 1-GlcNAc. However, when GS activation was achieved via the adenosine analogue and kinase inhibitor, 5'-iodotubercidin (ITU), subsequent addition of 1-GlcNAc allowed continued activation of GS. Phosphorylation of 1-GlcNAc in rat hepatocytes was established using radiolabelled material. The rate of phosphorylation was 1.60 nmol/min per 10(6) cells at 20 mM 1-GlcNAc but was reduced by the presence of 50 microM ITU (0.775 nmol/min per 10(6) cells). It is suggested that the phosphorylated derivative of 1-GlcNAc formed in hepatocytes is 1-GlcNAc 6-phosphate and that the presence of this species is responsible for the failure of 1-GlcNAc to activate GS. The relative importance of the reduction in concentration of GPa versus increased glucose 6-phosphate levels for activation of GS is discussed.
已设计、合成了一系列糖原磷酸化酶b(GPb)的葡萄糖类似物抑制剂,并对其进行了晶体学结合和动力学研究。目的是制备一种化合物,该化合物对糖原代谢的控制可能比母体葡萄糖分子更有效,并且可以缓解II型糖尿病中的高血糖症。N-乙酰-β-D-吡喃葡萄糖胺(1-GlcNAc)在粗提物中对肌肉GPb的Ki为30μM,比β-D-葡萄糖低367倍[博德、哈德温和约翰逊(1995年),《欧洲生物化学杂志》228卷,753 - 761页]。在当前工作中,报道了1-GlcNAc对无细胞制剂和分离的肝细胞中GP和糖原合酶(GS)激活状态的影响。在缺乏用于激酶活性的ATP的肝脏凝胶过滤提取物中,1-GlcNAc使GP迅速且随时间失活,随后激活GS。1-GlcNAc对这两种酶的作用比葡萄糖更强,0.8 mM的1-GlcNAc与50 mM葡萄糖等效。在1 mM时,1-GlcNAc增强了肝脏提取物(600%)和肌肉提取物(75%)对外源GPa的去磷酸化作用。这对于肝脏活性而言比葡萄糖提高了约500倍,对于肌肉活性提高了40倍。在完整的肝细胞中,1-GlcNAc对GP失活的葡萄糖效应增强了约5倍,但未能引发GS的激活。在完整的肝细胞中,随后添加1-GlcNAc可逆转葡萄糖诱导的GS激活。然而,当通过腺苷类似物和激酶抑制剂5'-碘结核菌素(ITU)实现GS激活时,随后添加1-GlcNAc可使GS持续激活。使用放射性标记物质确定了大鼠肝细胞中1-GlcNAc的磷酸化情况。在20 mM 1-GlcNAc时,磷酸化速率为每10⁶个细胞1.60 nmol/分钟,但50μM ITU的存在使其降低(每10⁶个细胞0.775 nmol/分钟)。有人提出,在肝细胞中形成的1-GlcNAc的磷酸化衍生物是1-GlcNAc 6-磷酸,并且该物质的存在是1-GlcNAc未能激活GS的原因。讨论了GPa浓度降低与葡萄糖6-磷酸水平升高对GS激活的相对重要性。